Tirzepatide 15mg
Dual GIP/GLP-1 receptor agonist — mid-range vial covering full titration through early maintenance.
Key Benefits
activates two complementary incretin pathways for superior metabolic response vs GLP-1 monotherapy
SURMOUNT-1 demonstrated 22.5% mean body weight reduction at 72 weeks, the highest of any approved weight-loss drug
reduces HbA1c by up to 2.46% in T2D research models, outperforming semaglutide in head-to-head trials
dual receptor activation produces stronger satiety signaling than single-receptor GLP-1 agonists
Active Signaling Pathway
Investigated Pathways
Proposed Mechanism
Tirzepatide is a 39-amino acid peptide with a C20 fatty diacid chain enabling albumin binding and a ~5-day half-life. It acts as a dual agonist at both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. GIP receptor activation adds complementary metabolic effects — enhanced insulin secretion, reduced glucagon, and direct adipocyte signaling — producing greater weight reduction than GLP-1 agonism alone.
Research Highlights
- SURMOUNT-1 trial: 22.5% mean body weight reduction at 15 mg/week over 72 weeks — the highest of any approved weight-loss drug at time of publication
- SURPASS-2 trial: tirzepatide 15 mg reduced HbA1c by 2.46% vs 1.86% for semaglutide 1 mg
- FDA approved as Mounjaro (T2D) in 2022 and Zepbound (obesity) in 2023
- Dual receptor mechanism produces additive metabolic effects beyond GLP-1 monotherapy
Randomised controlled trial data available. Results are compound-specific and do not constitute treatment guidance.
For laboratory research only
All Research Systems →For research use only — not for human consumption. No treatment claims.
Full Research Hub →How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 15mg vial — and when to plan your next order.
Vial supply estimate is based on standard research protocol volumes. Actual duration will vary based on your specific protocol design.
Scientific Background
Mechanism of Action
Tirzepatide is a 39-amino acid peptide with a C20 fatty diacid chain enabling albumin binding and a ~5-day half-life. It acts as a dual agonist at both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. GIP receptor activation adds complementary metabolic effects — enhanced insulin secretion, reduced glucagon, and direct adipocyte signaling — producing greater weight reduction than GLP-1 agonism alone.
Clinical Context
Tirzepatide represents the second generation of incretin-based therapy. Its dual mechanism — acting on both GIP and GLP-1 receptors — produces metabolic effects that exceed GLP-1 monotherapy in head-to-head trials. The 15mg vial bridges the full titration phase and the initial maintenance step, reducing the number of vials needed in the first 12 weeks of a protocol.
Research Highlights
- SURMOUNT-1 trial: 22.5% mean body weight reduction at 15 mg/week over 72 weeks — the highest of any approved weight-loss drug at time of publication
- SURPASS-2 trial: tirzepatide 15 mg reduced HbA1c by 2.46% vs 1.86% for semaglutide 1 mg
- FDA approved as Mounjaro (T2D) in 2022 and Zepbound (obesity) in 2023
- Dual receptor mechanism produces additive metabolic effects beyond GLP-1 monotherapy
Storage & Reconstitution
Store lyophilized at -20°C. Reconstitute with bacteriostatic water (BAC water). Recommended: add 3 mL BAC water to the 15 mg vial → yields 5 mg/mL. On a 100-unit insulin syringe, 1 unit = 50 mcg; 50 units = 2.5 mg (starter dose); 100 units = 5 mg (escalation dose). Inject BAC water slowly down the vial wall — do not shake, gently swirl. Stable 28 days at 2–8°C after reconstitution. Do not freeze reconstituted solution.
Key Studies
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff AM et al.
Tirzepatide 15 mg/week produced 20.9% mean body weight reduction at 72 weeks — highest of any approved weight-loss drug at time of publication.
PubMed →Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
Frías JP et al.
Tirzepatide 15 mg reduced HbA1c by 2.46% vs 1.86% for semaglutide 1 mg — superior glycemic control in head-to-head trial.
PubMed →Tirzepatide cardiovascular outcomes trial (SURPASS-CVOT)
Dahl D et al.
Tirzepatide demonstrated favorable cardiometabolic profile with significant reductions in cardiovascular risk markers.
PubMed →Pharmacokinetics
Bioavailability indicates how much of the compound reaches systemic circulation. Peak plasma is when blood levels are highest. Half-life determines dosing frequency — compounds with short half-lives require more frequent dosing to maintain therapeutic levels.
The volume of distribution reflects how widely the compound distributes into tissues. A higher Vd means the compound concentrates in tissues rather than staying in plasma.
Receptor Binding Profile
Appetite suppression, insulin secretion, gastric emptying delay
Enhanced insulin secretion, adipocyte lipolysis — dual mechanism superior to GLP-1 alone
Stronger satiety signaling than single-receptor GLP-1 agonists
Glucose-dependent insulin secretion via dual incretin pathway activation
Side Effects & Adverse Events
- Nausea (33%)
- Diarrhea (23%)
- Vomiting (18%)
- Constipation (17%)
- Injection site reactions
- Decreased appetite
- Fatigue
- Pancreatitis (rare)
- Gallbladder disease
- Thyroid C-cell tumors (rodent data)
Contraindications & Interactions
Synergistic Compounds
Lipo-C provides B12 repletion and lipotropic support during tirzepatide caloric restriction.
Lipo-C 1 mL IM 2–3× per week alongside weekly tirzepatide injection.
View Compound →Adding amylin receptor agonism to dual GIP/GLP-1 agonism for triple-mechanism weight loss.
Tirzepatide 5 mg + Cagrilintide 1.2 mg, both once weekly SubQ — titrate each independently.
View Compound →Transparent Global Sourcing
Manufactured
Sourced through our manufacturing partner in China
Independent Testing
Analytical reports available from Janoshik Analytical
Batch Verification
Batch-specific COAs with online verification via janoshik.com
US Fulfillment
Orders fulfilled from the United States